Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency

• Weike Bao,

  Affiliation Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• Karpagam Aravindhan,

  Affiliation Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• Hasan Alsaid,

  Affiliation Clinical Imaging Center, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• Thimmaiah Chendrimada,

  Affiliation Clinical Imaging Center, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• Matthew Szapacs,

  Affiliation Platform Technology and Science, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• David R. Citerone,

  Affiliation Platform Technology and Science, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• Mark R. Harpel,

  Affiliation Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• Robert N. Willette,

  Affiliation Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• John J. Lepore,

  Affiliation Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• Beat M. Jucker

  * E-mail: Beat.M.Jucker@gsk.com

  Affiliation Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯